Patients are already asking about peptides. They may hear about BPC-157 on a podcast, discover a peptide through a longevity clinic, or arrive with screenshots and online protocols. Some may even have purchased a product before discussing it with their physician.
Peptide therapy is already part of the conversation in medical practice. The question is no longer whether physicians will encounter these compounds. The more useful question is how to evaluate them when patients bring them up.
For physicians, that requires more than recognizing the name of a molecule. They need to look at the available evidence, understand the intended use, consider the patient’s clinical context, and know what information should guide the treatment discussion.
Not all peptide therapies belong in the same conversation
This matters because the term peptide covers a wide range of therapies. Some peptide-based drugs have FDA-approved indications, while others may be used off-label. There are also compounds that remain investigational or have much more limited human evidence.
Compounded preparations add another consideration. Their formulation, concentration, and source can differ from commercially approved products. For that reason, physicians should identify exactly which product they are evaluating as part of the clinical assessment.
Tesamorelin and BPC-157 illustrate how different two peptides can be. Tesamorelin has an FDA-approved indication and a substantial body of human clinical research. BPC-157 has attracted growing interest, but its human evidence remains far more limited. Both may appear in the same conversation, yet physicians need different frameworks to evaluate each one.
Before asking, “Which peptide should I use?” it helps to begin with three questions: What is the product? What evidence supports the proposed use? How does it fit the patient’s clinical situation?
This article offers a practical framework for answering those questions. It explores evidence, patient selection, informed consent, documentation, monitoring, and follow-up so physicians can approach peptide therapy with greater structure and clinical context.
This material provides educational information only. It does not provide medical or legal advice, establish a standard of care, or replace guidance from relevant medical boards, regulatory authorities, institutional policies, or legal counsel.
Before the Protocol: Understand What the Patient Is Asking You to Prescribe
Today, peptide therapy discussions often begin outside the medical office. Patients encounter these compounds through social media, podcasts, wellness clinics, fitness communities, and direct-to-consumer platforms.
By the time they speak with a physician, some patients already have a specific product in mind. They may know the compound name, proposed dose, injection schedule, or even the source. This means the conversation may begin with an expectation rather than an open clinical question.
For physicians, the first step is to bring that conversation back into a medical framework. What is the patient trying to address? What evidence supports the proposed use? Are there established alternatives? These questions help place the patient’s interest in the right clinical context.
Product source can also become relevant, especially when patients purchase peptides online. Health Canada, for example, has issued warnings about unauthorized injectable products marketed as BPC-157, CJC-1295, ipamorelin, GHK-Cu, and other compounds.
Physicians may therefore meet patients who already have access to a product before any medical evaluation has taken place. In those situations, the goal is to understand what the patient is considering, review the available evidence, and guide the conversation with appropriate clinical judgment.
Dismissing the topic immediately may close an important opportunity for education. At the same time, a patient’s interest in a compound should not replace a structured medical assessment.
Throughout this article, we will look at how physicians can compare different types of peptide therapies, assess the strength of the available evidence, and build a more consistent approach to patient selection, documentation, monitoring, and follow-up.
- Dr. Greg Jones, NMD, is an ISSCA Certified Instructor and Scientific Advisory Board Member with more than 15 years of clinical experience in regenerative and functional medicine, including peptide-based protocols. Dr. Jason Pencek, DC, FNP, is also an ISSCA Certified Instructor and Scientific Advisory Board Member with more than a decade of experience in regenerative medicine and clinical peptide applications.
“Peptides are a gray area” does not tell the whole story
The phrase “gray area” appears frequently in discussions about peptide medicine. However, it can oversimplify a field where different products have very different levels of evidence, approved uses, and clinical considerations.
Rather than treating peptide therapy as a single category, physicians can look at each product individually. Tesamorelin is a useful example because it has a clearly defined indication and established prescribing information.
EGRIFTA WR contains tesamorelin and is FDA approved for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Its prescribing information also helps define where the available evidence and approved use begin and end.
For example, it is not indicated for weight-loss management. The label also includes guidance on contraindications, monitoring, and factors such as IGF-1 levels, glucose intolerance, and malignancy-related considerations.
For physicians, this creates a clearer starting point. The product has an approved indication, published clinical data, and FDA-reviewed prescribing information that can help guide evaluation and patient discussions.
Off-label prescribing is different
Once a drug has received FDA approval, physicians may generally prescribe it for an unapproved use when they determine that the use is medically appropriate for a patient. FDA has already reviewed the drug itself in that situation, but it has not approved the specific off-label use.
That distinction is important because off-label prescribing is different from using a compound that has never received FDA approval. An approved drug may already have established manufacturing standards and safety information, while researchers may still have limited evidence for a new indication or evidence drawn from a different patient population.
Physicians should also consider the requirements that apply to their own practice. In the United States, state authorities primarily regulate medical practice and professional licensure, so local rules may influence how physicians evaluate and use certain therapies.
Off-label use of an FDA-approved drug and use of an unapproved compound are different situations. Understanding that difference helps physicians interpret the evidence more accurately and make better-informed clinical decisions.
A compounded preparation
Compounded preparations introduce another layer to the discussion. Unlike FDA-approved drugs, they do not go through the same premarket review for safety, effectiveness, and quality.
In the United States, compounding operates under specific federal pathways, including sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Each pathway has different requirements, so physicians should understand how the preparation they are considering fits within that framework.
The product itself also matters. Concentration, formulation, source, route of administration, and dosing instructions can all influence how physicians use a preparation in practice.
FDA reports involving compounded injectable semaglutide offer a useful example. Some dosing errors were linked to differences in concentration, syringe measurements, or confusion when doses were expressed in “units.”
For physicians, the broader lesson is practical. Physicians should evaluate each compounded preparation as a specific product, paying attention to its formulation, administration, and the evidence available to support its use.
An unapproved or investigational peptide
Several compounds discussed in peptide medicine do not have FDA-approved indications, and some still have limited human clinical evidence. BPC-157 and CJC-1295 are examples that appear frequently in current peptide conversations.
The available information can vary significantly from one compound to another. In some cases, important questions remain around safety data, product quality, immunogenicity, or the effects of different routes of administration.
For physicians, market visibility does not necessarily reflect the strength of the clinical evidence. A product may attract widespread attention or become commercially available even when important questions about its use remain unanswered.
The same applies to products labeled “research use only.” That designation does not make them approved therapeutic products, and Health Canada has noted that products marketed for research purposes may still fall under regulatory requirements when they are sold or represented for human use.
The practical takeaway is straightforward. Physicians should identify the exact product, understand what evidence is available, and place that information in the appropriate clinical and regulatory context before making a treatment decision.
A better question than “Is peptide therapy legal?”
A yes-or-no answer is rarely enough. A more useful approach is to begin with a few practical questions. Which molecule is being discussed? How does the proposed use fit the patient’s situation? What evidence supports it in that particular patient population?
Physicians can then look at the product itself. Does an approved formulation exist? Is the proposed use on-label or off-label? Could the preparation be compounded or come from another source? These details help place the therapy in the right clinical context.
The answers may differ from one peptide to another. They can also vary between countries, since approval pathways, prescribing requirements, and professional standards are not identical across jurisdictions.
Canada, for example, regulates injectable peptide drugs as prescription drugs and has taken action against the sale of unauthorized injectable products. Requirements across Latin America also vary by country, which makes local context important when evaluating a therapy.
For physicians, the goal is to develop a framework that can adapt to those differences. The same core questions can help evaluate the product, the available evidence, the proposed use, and the patient’s individual needs.
Regulatory status remains part of that assessment, but it is one piece of a broader clinical picture. As evidence, products, and indications evolve, physicians should be prepared to reassess the information supporting their decisions.
The peptide conversation without a system
Consider a common scenario. A patient asks about a specific compound, and the physician reviews the available information before deciding how to proceed. Relevant contraindications may be considered, and informed consent may also be part of the discussion.
Even then, important questions can remain. Was the treatment objective clearly defined? Was the strength of the evidence discussed? Were reasonable alternatives considered?
The same applies to follow-up. Were baseline measurements established? Was the product source documented when relevant? Was there a clear plan for monitoring response and deciding whether treatment should continue?
The challenge is not always a lack of knowledge. More often, physicians need a repeatable process that helps organize the information they already have.
Without that structure, each new peptide request can feel like starting from zero. A consistent framework makes the decision-making process easier to apply across different compounds and patient scenarios.
The same conversation with a documented framework
A structured approach starts with the patient’s objective. The physician identifies what the patient wants to improve and considers whether that request aligns with a recognized diagnosis, symptom pattern, or clinical goal.
The next step is to evaluate the compound itself. Physicians can look at its approved uses, available human data, and how that evidence compares with animal studies, mechanistic research, or anecdotal reports.
From there, the physician reviews relevant risks, contraindications, and reasonable alternatives. The treatment plan should also include measurable endpoints, a follow-up schedule, and clear criteria for reassessment or discontinuation.
The reasoning should be visible in the medical record. This does not remove uncertainty, but it helps physicians manage it in a consistent and transparent way.
Informed consent is part of that process. The American Medical Association describes it as a discussion that should include the nature and purpose of the intervention, relevant risks, expected benefits, available alternatives, and the option of declining treatment.
That conversation should also be documented. A signed form may support the process, but it should not replace the discussion itself. Another physician reviewing the chart should be able to understand why the decision was made.
Once that framework is in place, the next question becomes more practical: what does a peptide protocol look like when physicians build it around clinical decisions rather than a list of doses?
A Protocol Is a Sequence, Not a List
A useful protocol begins before the first dose. Physicians sometimes reduce peptide protocols to a table that lists the compound, dose, frequency, and duration. Those details matter, but they represent only one part of the process.
A stronger protocol should define the physician’s goals, specify how physicians will measure progress, and establish when they should reassess the plan.
That process starts with the patient’s clinical objective. What does the patient want to improve? Is that goal clearly defined, and can the outcome be measured over time?
The physician then establishes the clinical context. Symptoms, diagnosis, medical history, medications, previous treatments, and relevant testing all help shape the decision. The proposed compound can then be evaluated based on its evidence, intended use, and place within the broader treatment plan.
From there, the physician reviews contraindications, alternatives, and baseline data. The exact approach will depend on the pharmacology of the product and the individual characteristics of the patient. Informed consent should reflect both what is known and where uncertainty remains.
The plan should also define follow-up. Physicians should define what they will monitor, when they will review progress, and which findings would prompt a change in treatment.
A complete protocol should guide the entire process, not just the beginning. It should help physicians start treatment thoughtfully, monitor it consistently, and know when reassessment or discontinuation is appropriate.
Two peptides can have very different evidence profiles
One of the clearest ways to understand this framework is to compare two compounds that often appear in peptide medicine. Tesamorelin and BPC-157 are both described as peptides, but the evidence behind them is very different.
Tesamorelin has an established clinical use supported by human studies, while BPC-157 remains an area of growing interest with much more limited human data.
For physicians, that contrast is useful because it shows why peptide therapies should be evaluated individually. The name of the category matters less than the quality of the evidence behind each compound.
Tesamorelin: a defined indication with human clinical evidence
Tesamorelin is a growth hormone-releasing factor analog. FDA has approved EGRIFTA WR in the United States for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The prescribing information limits that approval to this specific indication and does not include general weight-loss management.
The evidence behind that use includes randomized controlled trials. A pooled analysis of two phase III studies included more than 800 antiretroviral-treated patients with HIV and excess abdominal fat. After 26 weeks, participants receiving tesamorelin showed a significant reduction in visceral adipose tissue compared with placebo.
Other randomized studies have reported similar reductions in visceral fat. Some research has also explored effects on liver fat and additional metabolic outcomes, although those findings should be interpreted within the populations and endpoints that were actually studied.
For physicians, this is a useful example of how a peptide can have a well-defined clinical evidence base. Randomized trials, phase III data, and established prescribing information support tesamorelin use in a specific patient population.
That does not mean it is appropriate for every patient. The prescribing information includes contraindications, warnings, and monitoring considerations related to factors such as active malignancy, pregnancy, glucose intolerance, IGF-1 levels, fluid retention, and disruption of the hypothalamic-pituitary axis.
The broader lesson is that evidence becomes most useful when it stays connected to the patient population, indication, and outcomes studied. Tesamorelin offers meaningful clinical data within those boundaries, while different uses may require a separate review of the available evidence.
BPC-157: clinical interest has moved faster than the human evidence
BPC-157 presents a very different evidence profile. Interest in the compound has grown, particularly in sports medicine, musculoskeletal recovery, and regenerative medicine. At the same time, most of the published research remains preclinical.
A 2025 systematic review examined BPC-157 in orthopedic sports medicine and identified 36 eligible studies. Thirty-five were preclinical, while only one involved human participants. Laboratory and animal research still account for most of the current evidence.
Human studies have begun to appear, but they remain small. One pilot study evaluated intravenous administration in two adults and reported no adverse effects during the short observation period. That provides an early human observation, although a study of that size cannot establish broad safety conclusions.
Another small pilot study examined BPC-157 in women with interstitial cystitis and reported symptom improvement. The study lacked a control group and included only a small number of participants, so researchers still need larger and more rigorous studies.
A later review of BPC-157’s translational development reached a similar conclusion. Available human data involved fewer than 30 participants across a small number of uncontrolled studies, highlighting how early the clinical research remains.
BPC-157 is also not FDA approved. FDA materials related to compounding have identified questions around safety data, immunogenicity, and peptide-related impurities that remain relevant when physicians evaluate the compound.
For physicians, the key point is that scientific interest and clinical certainty are not the same thing. BPC-157 has generated promising preclinical findings, but its human evidence base is still developing.
That distinction helps physicians interpret emerging research without dismissing it or overstating what is currently known. In this context, “promising” describes an area worth studying further, not a guaranteed clinical outcome.
“But I know someone who says it worked”
This question comes up often. A patient may know an athlete, friend, or online personality who reports a positive experience with a peptide. That experience can be part of the conversation, but it should not be treated as proof of efficacy.
Many factors can influence how a patient feels over time. Injuries may improve naturally, rehabilitation may help, and changes in sleep, nutrition, activity, or other treatments can all affect the outcome.
Product variability can also play a role. Preparations from different sources may not be identical, which makes personal experiences even harder to compare directly.
For physicians, the challenge is to help patients understand the difference between an individual experience and a broader body of evidence. Mechanistic research may explain how a compound could work, while animal studies can reveal potential biological effects.
Case reports and small pilot studies may then generate useful hypotheses. Larger, well-designed randomized trials can provide a clearer picture of how a therapy performs in a defined patient population.
Systematic reviews help physicians place individual findings in context by comparing results across multiple studies. The goal is not to turn the consultation into a statistics lecture, but to help patients understand what the evidence shows, what remains uncertain, and how that information should guide the decision.
Illustrative clinical scenario
The following scenario is educational and does not describe a real ISSCA patient. A 46-year-old recreational athlete presents with persistent Achilles discomfort and asks about BPC-157 after hearing about it through podcasts and online communities.
A limited approach might begin by discussing the compound itself. A more structured approach starts with the patient. How long has the pain been present? Has the patient received an appropriate evaluation? Would imaging or further assessment add useful information?
The physician should also review what has already been tried. Rehabilitation, activity modification, medication history, comorbidities, and other relevant factors may all influence the next step.
The patient’s objective comes next. Is the goal to reduce pain, improve function, return to activity sooner, or address several of these concerns? Whenever possible, physicians should define those goals in measurable terms so they can track progress over time.
The physician can then evaluate BPC-157 within that broader clinical picture. What human evidence is available? How closely does it match this patient’s situation? What questions remain unanswered? Established alternatives should also be part of the discussion when they are relevant.
At that point, the decision becomes easier to place in context. Whether the physician decides to pursue the requested therapy, recommend another option, or continue evaluating the patient, the reasoning behind that decision should be clear.
This is where a protocol becomes useful. It turns a series of individual questions into a repeatable process, so physicians do not have to rebuild their approach every time a new peptide enters the conversation.
Informed consent should be a process
An informed-consent document can be useful, but the conversation behind it matters more. The American Medical Association advises physicians to explain the nature and purpose of an intervention, along with expected benefits, relevant risks, alternatives, and the option of declining treatment.
Physicians should also explain how certain the available evidence is. In peptide medicine, that may include what research already supports, how physicians currently understand the proposed use, and which questions still need answers.
They should discuss known adverse effects and meaningful limitations in the available data and also review reasonable alternatives and explain the monitoring plan.
Patients should understand the treatment goal, how physicians will evaluate progress, and which findings may lead to a change or discontinuation of the plan.
Documentation supports that process, but a signed form should not replace a treatment-specific discussion. Informed consent is most useful when it reflects the actual product, the proposed use, the available evidence, and the patient’s individual situation.
Documentation should tell the clinical story
Imagine that the patient changes physicians tomorrow. Could the next physician understand why the previous physician made that treatment decision? A well-documented medical record should make the reasoning clear.
The chart should explain why the patient presented, which clinical objective the physician identified, and which options they considered. It should also show the evidence that informed the decision, along with relevant contraindications and risk factors.
Physicians should also document the consent discussion, including relevant risks, uncertainties, alternatives, and the agreed treatment plan. The record should reflect what the physician and patient actually discussed.
Product details may also matter, especially with compounded preparations. Physicians can document the source, formulation, and other relevant information to provide context for future follow-up.
The record should also explain what physicians will monitor and when they will reassess the patient. Because documentation requirements vary across countries, states, institutions, and specialties, physicians should follow the standards that apply to their own practice.
Across those different settings, one principle remains useful: the reasoning behind the decision should be easy to understand.
From the first visit to follow-up
A protocol should make clinical care more organized, not more complicated. During the first visit, physicians should define the patient’s goal and establish the clinical context. They should review relevant history, diagnosis, previous treatments, medications, and baseline findings.
The physician then evaluates the proposed compound within that context. Its evidence base, intended use, and relevance to the patient’s situation should be clear before moving forward.
Physicians should next determine whether the patient is an appropriate candidate. They should review contraindications and consider whether the therapy or the patient’s history requires additional evaluation.
During treatment planning, physicians should discuss expected benefits, known risks, important uncertainties, and reasonable alternatives. They should also establish measurable endpoints to track progress over time.
Once treatment begins, follow-up should answer a practical question: is the patient improving, and does the current plan still make sense? The physician can compare the patient’s status with the original baseline and look for changes that may affect the benefit-risk assessment.
Continuation should remain an active clinical decision rather than an automatic next step. Lack of meaningful benefit, adverse effects, new contraindications, changes in health status, or new information may all justify reassessment.
The exact criteria will vary depending on the therapy. Even so, the principle is consistent: a strong protocol should guide physicians through the full treatment cycle, including when to continue, adjust, or stop.
“ISSCA has one of the best programs internationally in regenerative medicine, anti-aging and functional medicine.”
Dr. Samantha Chen, NMD · Canada
What structured peptide education should provide
Useful peptide education should go beyond pharmacology. Physicians need a practical way to move from a patient’s question to a well-supported clinical decision.
That requires several areas of knowledge to work together. Mechanism of action and clinical evidence are essential, but so are patient selection, contraindications, informed consent, documentation, monitoring, and follow-up.
Structured education can help physicians recognize where the evidence is strong, where important questions remain, and how those differences should influence clinical decisions. This becomes especially valuable in a field where patient interest can move faster than formal research.
It also helps set the right expectations. Physicians who want to work responsibly with peptide therapies need more than a list of compounds and doses. They need to understand the evidence, the patient context, and the reasoning behind each decision.
Protocols can support that process by giving physicians a consistent way to organize what they know and apply it in practice.
That leads to a more useful question: where can physicians build the knowledge and structure they need when these conversations begin in the clinic?
Building a Framework You Can Bring Back to the Clinic
Physicians have access to more medical information than ever before. They can search PubMed, watch lectures, attend conferences, review pharmacology papers, listen to podcasts, and compare different protocols.
Even with all of those resources, translating information into practice can still be difficult. The patient in front of you will rarely match the exact population described in a study.
They may take several medications, have multiple diagnoses, or arrive with strong expectations shaped by testimonials, social media, or previous experiences.
That is why physicians need more than knowledge about individual compounds. They need a clear way to organize the evidence and apply it to the patient in front of them.
Physicians need to understand the science, evaluate the patient, and recognize the limits of the available data. The ISSCA Advanced Peptide Therapy Certification addresses that educational need.
The ISSCA Advanced Peptide Therapy Certification follows a structured path from peptide fundamentals to clinical application. Across 9 modules and 52 lessons, physicians explore mechanisms of action, therapeutic classification, patient evaluation, protocol and dosing frameworks, monitoring, and practical considerations for integrating peptide therapy into medical practice.
The curriculum also examines peptide applications across immune, neuroendocrine, metabolic, regenerative, cognitive, and other clinical areas. Physicians can use the program to strengthen how they evaluate evidence, organize treatment decisions, and approach peptide protocols within a broader clinical framework.
Education shaped by real clinical conversations
ISSCA has developed its peptide therapy program through physician education at live scientific events and congresses. The program has included learning experiences in locations such as Cancún, Lisbon, Punta Cana, and Buenos Aires.
That experience brings the discussion closer to real medical practice. Physicians can explore questions that often come up when evaluating peptide therapies and compare perspectives with other professionals facing similar decisions.
Many of those questions are familiar. How strong is the evidence? Which patients may be appropriate candidates? What should physicians document, monitor, or reassess over time?
These conversations help connect pharmacology with everyday decision-making. They also give physicians a more structured way to think about peptide therapy beyond individual compounds or isolated protocols.
Start with the part of the framework you need first
Not every physician is ready to begin with a complete certification. Some may want to start with the fundamentals, while others may prefer to see how physicians build a structured peptide therapy protocol.
For that reason, ISSCA offers two ways to begin. Both draw from the broader educational framework of the Advanced Peptide Therapy Certification.
These entry points allow physicians to explore the methodology, strengthen their foundation, and decide whether they want to continue into the full certification.
Start with the foundations before building the protocol
When patients ask about peptide therapy, physicians do not need to begin by memorizing more compounds. A stronger starting point is understanding how to evaluate the therapy, the evidence, and the patient context.
ISSCA offers the Foundations of Peptide Therapy module as a standalone introduction to that approach. It gives physicians a way to begin exploring the core concepts before moving into the full Advanced Peptide Therapy Certification.
The Foundations of Peptide Therapy module includes five lessons that introduce physicians to the core concepts behind peptide medicine. Topics include therapeutic peptides, the evolution of peptide therapy, mechanisms of action, therapeutic classification, and the clinical considerations involved in integrating peptides into medical practice.
The module also includes six downloadable resources: case studies, ISSCA Protocols Chapter 1, the Spanish edition of Protocols Chapter 1, Foundations of Peptide Therapy slides, the Therapeutic Peptides book, and the Cellgenic Catalog 2026.
This entry module gives physicians a structured way to explore the foundations of peptide therapy before deciding whether they want to continue into the complete ISSCA Advanced Peptide Therapy Certification.
Build the framework first. Then decide how far you want to take your training.
Turn knowledge into a repeatable workflow
Reading about peptide therapy is one thing. Applying the same clinical reasoning consistently across different patients is another.
That is where a structured workflow can help. ISSCA is also evaluating an entry product built around selected clinical protocols and checklists from its peptide therapy educational materials.
The goal is to give physicians practical tools that help organize patient assessment, treatment planning, documentation, monitoring, and follow-up in a more consistent way.
This package brings together selected clinical resources from the ISSCA Advanced Peptide Therapy Certification. Depending on the final approved configuration, it may include protocol sheets, peptide selection guides, dosing frameworks, case-based resources, and other practical tools used throughout the program.
The goal is to give physicians a more structured way to organize patient evaluation, treatment planning, documentation, monitoring, and follow-up. These resources support clinical decision-making but do not replace prescribing information, individualized patient assessment, or the professional requirements that apply to each physician’s practice.
If a physician later enrolls in the full ISSCA Advanced Peptide Therapy Certification, ISSCA can apply the amount paid for the package toward the complete program, subject to the final approved offer terms.
Explore clinical tools developed for physicians studying this field.
A final question worth asking
Patients will continue hearing about peptides. New compounds will enter the conversation, and existing therapies will continue to be studied in new clinical contexts.
Some early hypotheses will gain stronger support as research evolves, while others may not. For physicians, that makes ongoing evaluation an important part of working in this field.
A strong approach starts with understanding the compound, reviewing the available evidence, and considering how it fits the individual patient. From there, physicians can define appropriate goals, monitor meaningful outcomes, and reassess the plan as new information becomes available.
A clinical framework gives physicians a consistent way to navigate those decisions. It helps physicians organize a rapidly evolving field into a structured process they can apply across different patients and therapies.
That is the difference between simply knowing the names of peptides and understanding how to evaluate peptide therapy in practice.
Ready to go deeper?
Explore ISSCA Advanced Peptide Therapy education and choose the starting point that best fits where you are in your learning journey.
Explore Peptide Therapy Education
Frequently Asked Questions About Peptide Therapy for Physicians
Are peptide therapies FDA approved? Some peptide-based drugs are FDA approved, but peptide therapy is not a single regulatory category. Tesamorelin, semaglutide, and other peptide medicines have approved products and indications, while other compounds do not.
For physicians, the important step is to evaluate the specific molecule, product, and proposed use rather than treating all peptides the same way.
Can a physician prescribe an FDA-approved drug off-label?
Physicians may generally prescribe an FDA-approved drug for an unapproved use when they determine that the use is medically appropriate.
In those cases, FDA has reviewed the drug itself but has not approved that specific off-label use. Physicians should also consider the professional and jurisdictional requirements that apply to their own practice.
Are compounded peptides FDA approved?
Compounded preparations do not receive FDA approval, and the FDA does not review them through the same premarket process for safety, effectiveness, and quality.
In the United States, compounding operates under specific frameworks, including sections 503A and 503B. Each pathway has its own requirements, which is why physicians should evaluate the preparation itself rather than assume that all compounded products are equivalent.
Is BPC-157 FDA approved?
No. BPC-157 is not FDA approved, and the available human clinical evidence remains limited.
Most of the research to date has been preclinical or based on small studies. FDA materials have also raised questions related to safety data, immunogenicity, and peptide-related impurities in the compounding context.
Is tesamorelin FDA approved?
Yes. FDA has approved EGRIFTA WR, which contains tesamorelin, for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
The approval applies to this specific use. Physicians should not interpret it as approval for general weight-loss management and should consider the studied population and intended use when reviewing the evidence.
What should informed consent for peptide therapy include?
Informed consent should reflect the specific therapy and the individual patient. Physicians should discuss the purpose of treatment, expected benefits, known risks, important uncertainties, reasonable alternatives, and the option of declining treatment.
Physicians should also document the conversation and the patient’s decision. When evidence is still developing or the proposed use is off-label, physicians may need to discuss those details in greater depth.
